Browse articles on EyeWorld.org from the Glaucoma section. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
The landscape of glaucoma surgery is a spectrum, ranging from selective laser trabeculoplasty to the more invasive heavy hitters still considered the gold standard for IOP lowering. In the middle are a wide range of MIGS options. Three glaucoma specialists discussed best practices for ab interno trabeculotomy, goniotomy, and canaloplasty.
A group of surgeons came together to draft and publish consensus guidelines for MicroPulse Transscleral Laser Therapy (Iridex). This therapy is used for a non-incisional laser glaucoma treatment that has been demonstrated to be safe and effective but does not have recommendations on optimal treatment protocols.
MIGS procedures have become a mainstay in the treatment of mild to moderate glaucoma, but what pressures can physicians realistically expect with these? Three surgeons spoke about this, as well as how MIGS can fit into the overall glaucoma management process and what to do if MIGS procedures don’t achieve the desired IOP.
There is a significant focus on stopping progression of optic nerve damage and subsequent vision loss in glaucoma, but what about patients who have already reached a point of vision loss? What modern visual rehabilitation technologies and services are available to them? EyeWorld spoke with three experts on this topic.
Patients with glaucoma who need cataract surgery have many lens options available, and it’s important for physicians to present the potential benefits and risks so patients can make the best decision. Two experienced ophthalmologists discussed different lens options for glaucoma patients and important factors to consider.
Glaucoma Editor Manjool Shah, MD, talks about what readers can expect in the Glaucoma section of the issue, as well as the value of ASCRS and the Annual Meeting. He also welcomes the newest members of the Glaucoma Editorial Board.
In the trial, 12-month mean IOP was lowered 40% from baseline with the biostent, with 80% of patients achieving at least a 20% reduction in IOP.
Source: Sean Ianchulev, MD, MPH
The first-in-human trial and data for suprachoroidal outflow enhancement using a novel micro-interventional technology and first-in-class biostenting approach developed by Sean Ianchulev, MD, MPH, was published online in the British Journal of Ophthalmology in January.
“A fundamental and unanswered question concerning all MIGS devices is whether they have any measurable ability to help POAG patients retain their vision.” The authors of a study published in the American Journal of Ophthalmology sought to answer this question. The study is a post-hoc visual field analysis of the 5-year HORIZON trial.
Constance Okeke, MD, is a wife, mother, surgeon, researcher, assistant professor, consultant, and a soon-to-be two-time book author. EyeWorld caught up with her to learn more about her latest written endeavor and get some insights on what the process of book writing is like for a busy ophthalmologist.
Nathan Radcliffe, MD
Glaucoma Editor
Glaucoma Editor Nathan Radcliffe, MD, spoke about EyeWorld’s approach to glaucoma management and introduced the new Glaucoma Editor, Manjool Shah, MD.
